Option chain shows key data for Nxu's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nxu.

Nxu (NASDAQ:NXU) Stock, Option Chain

Nxu Inc is a technology company developing next-generation electric vehicle (EV) charging, battery, and vehicle technologies for mobility customers. Its technology company building energy and infrastructure solutions for consumers and businesses. Its NxuOne charging technology provides repeatable, consistent power delivery, designed to meet the needs of today's electric vehicles as well as those developed in the future.

Crude Oil 6- logo

BYON

MRNS

Crude Oil Down 1%; Dow Posts Upbeat Earnings

Kaufbeuren,,Germany,-,April,26,,2021:,Honeywell,Company,Logo,On

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results

wall-street-ai18

LGCB

LILM

ORKT

TSLA

Dow Falls 150 Points; Tesla Posts Upbeat Earnings

Nxu Inc

VSE plans to add an additional 110 new employees over the next five years, supporting the existing base of approximately 250 South Florida based employees.&nbsp;
The Company also intends to invest approximately $3.5 million in tenant improvements, including new offices, additional MRO capabilities, a training and conference center, and renovations to existing spaces.

VSEC

VSE Plans Relocation Of Its Corporate Headquarters To Miramar, Florida

Earnings Beats

CRNC

Cerence Q4 2024 Adj. EPS $(0.07) Beats $(0.36) Estimate, Sales $54.805M Beat $47.650M Estimate

Across the recent three months, 31 analysts have shared their insights on Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $412.39, a high estimate of $505.00, and a low estimate of $300.00. Experiencing a 8.71% decline, the current average is now lower than the previous average price target of $451.72. 
<img src="https://www.benzinga.com/files/images/story/2024/1732190443_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ulta Beauty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$472.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$380.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$395.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$357.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$424.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$390.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$395.00</td>
<td>-</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Sell</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$450.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$345.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$442.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$335.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$505.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$385.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$356.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$385.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$448.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$522.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ulta Beauty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ulta Beauty's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ulta Beauty's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ulta Beauty analyst ratings.</a>
<h2>Unveiling the Story Behind Ulta Beauty</h2>
With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
<h3>Ulta Beauty: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Ulta Beauty's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.88% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Ulta Beauty's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.87%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ulta Beauty's ROA stands out, surpassing industry averages. With an impressive ROA of 4.44%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ulta Beauty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ULTA

Breaking Down Ulta Beauty: 31 Analysts Share Their Views

Citigroup analyst Spiro Dounis upgrades DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) from Neutral to Buy and raises the price target from $90 to $115.

Upgrades

Price Target

Citigroup Upgrades DT Midstream to Buy, Raises Price Target to $115

Ratings for Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Piedmont Lithium, revealing an average target of $12.97, a high estimate of $31.00, and a low estimate of $7.80. Highlighting a 28.42% decrease, the current average has fallen from the previous average price target of $18.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1732190436_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Piedmont Lithium among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin Yun</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Neutral</td>
<td>$13.50</td>
<td>-</td>
</tr>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$9.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Hayden Bairstow</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Underperform</td>
<td>$7.80</td>
<td>-</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.50</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Piedmont Lithium. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Piedmont Lithium compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Piedmont Lithium's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Piedmont Lithium's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PLL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Piedmont Lithium analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Piedmont Lithium's Background</h2>
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
<h3>Piedmont Lithium's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Piedmont Lithium's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -41.3% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Piedmont Lithium's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -60.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Piedmont Lithium's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.7%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Piedmont Lithium's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.99%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Piedmont Lithium adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Piedmont Lithium Through The Eyes Of 6 Analysts

Analysts' ratings for DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $89.56, a high estimate of $115.00, and a low estimate of $74.00. Witnessing a positive shift, the current average has risen by 14.5% from the previous average price target of $78.22.
<img src="https://www.benzinga.com/files/images/story/2024/1732190429_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of DT Midstream by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$89.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DT Midstream. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DT Midstream compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DT Midstream's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DT Midstream's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DTM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DT Midstream analyst ratings.</a>
<h2>Unveiling the Story Behind DT Midstream</h2>
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
<h3>DT Midstream: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, DT Midstream showcased positive performance, achieving a revenue growth rate of 5.98% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: DT Midstream's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 35.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DT Midstream's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): DT Midstream's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.0%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.65.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down DT Midstream: 9 Analysts Share Their Views

Throughout the last three months, 4 analysts have evaluated UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $131.5, a high estimate of $156.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 16.89% increase from the previous average price target of $112.50.
<img src="https://www.benzinga.com/files/images/story/2024/1732190418_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive UMB Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$127.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of UMB Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UMB Financial's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UMB Financial analyst ratings.</a>
<h2>All You Need to Know About UMB Financial</h2>
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.
<h3>UMB Financial: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: UMB Financial's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 13.47%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: UMB Financial's net margin is impressive, surpassing industry averages. With a net margin of 30.13%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): UMB Financial's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.24%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): UMB Financial's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.24%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.18, UMB Financial adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

Decoding 4 Analyst Evaluations For UMB Financial

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $45.35, a high estimate of $92.00, and a low estimate of $24.00. A 23.06% drop is evident in the current average compared to the previous average price target of $58.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1732190409_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Apellis Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Apellis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Key Indicators: Apellis Pharmaceuticals's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 78.29% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -29.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -22.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts

On August 22, 2024, the Company previously guided to fiscal 2024 comparable club sales, excluding the impact of gasoline sales, at the high end of a 1% to 2% year-over-year growth range; fiscal 2024 merchandise gross margins to be approximately flat year-over-year; and fiscal 2024 adjusted EPS potentially toward the low end of a $3.75 to $4.00 range.

Guidance

General

BJ's Wholesale Club Expects FY24 Comparable Club Sales, Excluding The Impact Of Gasoline Sales, To Increase 2.3%-2.4% YoY Compared To Prior Guidance Of At The High End Of 1%-2%

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

BJ's Wholesale Club Expects Q4 FY24 Comparable Club Sales, Excluding The Impact Of Gasoline Sales, To Increase 2.5%-3.0% YoY

"As we look ahead, we remain confident in our ability to drive long-term growth and shareholder value led by our continued focus on our strategic priorities," said Laura Felice, Executive Vice President, Chief Financial Officer, BJ's Wholesale Club. "We expect fourth quarter fiscal 2024 comparable club sales, excluding the impact of gasoline sales, to increase 2.5% to 3.0% year-over-year, bringing the full year fiscal 2024 growth to between 2.3% and 2.4%. We continue to expect fiscal 2024 merchandise gross margins to remain approximately flat year-over-year. Finally, we expect fourth quarter fiscal 2024 adjusted EPS to range from $0.78 to $0.88, bringing the full year fiscal 2024 range to $3.90 to $4.00."

Retail Sales

BJ's Wholesale Club Expect Q4 FY24 Adjusted EPS Of $0.78-$0.88, With FY2024 Adjusted EPS Of $3.90-$4.00 Versus Prior Guidance Of $3.75-$4.00 And Consensus Of $3.84

Barclays analyst Brian Morton downgrades Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) from Equal-Weight to Underweight and lowers the price target from C$80 to C$79.

Downgrades

TSX:TD

Barclays Downgrades Toronto-Dominion Bank to Underweight, Lowers Price Target to C$79

Receiving the Eichrecht certification marks a significant step towards Wallbox's expansion into DC fast charging in one of Europe's largest EV markets, and the launch of Wallbox's highest Power-to-Footprint ratio charger yet.

Wallbox Says Its Supernova DC Fast Charger Certified For Conformity According To Germany's Eichrecht Regulation

HC Wainwright &amp; Co. analyst Yi Chen maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and lowers the price target from $40 to $36.

RGNX

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $36

The applicable waiting period under the HSR Act expired at 11:59 p.m., Eastern time, on November 20, 2024.&nbsp;
The expiration of the waiting period under the HSR Act satisfies an important condition necessary for the completion of the Proposed Transaction, which is expected to close by the end of the third quarter of 2025, and remains subject to other conditions and regulatory approvals.
 &nbsp;

EVRI

IGT Reports Expiration Of HSR Act Waiting Period, In Connection With Proposed Deal Whereby IGT Gaming And Everi Will Be Simultaneously Acquired By Newly Formed Holding Company Owned By Apollo

Barclays analyst Brian Morton upgrades Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) from Equal-Weight to Overweight and raises the price target from C$150 to C$180.

TSX:RY

Barclays Upgrades Royal Bank of Canada to Overweight, Raises Price Target to C$180

Buybacks

BJ's Wholesale Club's Board Approves New $1B Share Repurchase Program

U.S. stocks could open on a negative note on Thursday after AI bellwether Nvidia Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors">guidance fell short</a> of some expectations. Futures of all three major indices were down as investors processed the AI giant's earnings.
Other chip makers like Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) also experienced pressure in premarket trading.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.33%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.08%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.25% to $589 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.34% to $501.46, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
The Dow Jones snapped its two-session losing streak this week to close 100 points higher on Wednesday, while the S&amp;P 500 eked a marginal gain to close in the green.
The tech-heavy Nasdaq, however, fell ahead of the volatility due to Nvidia's earnings after the bell.
Crude oil prices continued to rise amid growing tensions between Russia and Ukraine but remained under the $70 mark.
Treasury yields eased slightly as investors waited for further economic data.
On the economic data front, mortgage applications in the U.S. rose 1.7% from the previous week in the week ending Nov. 15, compared to a 0.5% gain in the prior period.
Most sectors on the S&amp;P 500 closed on a positive note, with healthcare, energy, and materials stocks recording the biggest gains on Wednesday.
However, consumer discretionary and financial stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.11%</td>
<td>18,966.14</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.002%</td>
<td>5,917.11</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.32%</td>
<td>43,408.47</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.03%</td>
<td>2,325.53</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, chief market strategist at Carson Group, maintained that despite the weakness in the markets currently, he remains optimistic about the potential of a continued bull run.
"Weakness right around now is perfectly normal. The good news is I wouldn&#8217;t give up on a late November rally."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Weakness right around now is perfectly normal. The good news is I wouldn&#39;t give up on a late November rally. <a href="https://t.co/NuU2qzpDsC">pic.twitter.com/NuU2qzpDsC</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1859314388739686769?ref_src=twsrc%5Etfw">November 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite the volatile movement in Nvidia and other chipmaker stocks, Wedbush analyst Dan Ives maintained optimism about the AI giant's performance.
"The Godfather of AI Jensen and Nvidia delivered a massive beat and big things ahead for Blackwell," Ives said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Godfather of AI Jensen and Nvidia delivered a massive beat and big things ahead for Blackwell as we discussed into this big night for the tech world on <a href="https://twitter.com/SquawkStreet?ref_src=twsrc%5Etfw">@SquawkStreet</a> &#x1f3c6;&#x1f525;&#x1f37f;&#x1f402;&#x1f4fa;&#x1f3a4;&#x1f447; <a href="https://t.co/6ehn8D3Gs0">https://t.co/6ehn8D3Gs0</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1859387551351546328?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Nvidia <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">posted third-quarter revenue</a> of $35.1 billion, up 94% year-on-year, beating the Street consensus of $33.12 billion, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">from Benzinga Pro</a>. This was the ninth straight quarter of Nvidia beating analyst estimates.
Tech bull Ives thinks that this is <a href="https://www.benzinga.com/markets/equities/24/11/42102642/nvidia-delivered-jaw-dropping-q3-earnings-says-dan-ives-this-is-the-fourth-revolution-playing-out-in-front-of-our-eyes">the "fourth revolution"</a> in technology, and it could help the Nasdaq surge to 25,000.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Thursday's economic calendar includes the release of initial jobless claims data.
<ul>
<li>Initial jobless claims data will be released at 8:30 a.m. ET.</li>
<li>Philadelphia Fed manufacturing survey will be released at 8:30 a.m. ET.</li>
<li>Cleveland Fed President Beth Hammack will speak at 8:45 a.m. ET.</li>
<li>Existing home sales data and leading economic index will be released at 10 a.m. ET.</li>
<li>Kansas City Fed President Jeff Schmid will speak at 1:10 p.m. ET.</li>
<li>Fed Vice Chair for Supervision Michael Barr will speak at 4:40 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.6% in premarket trading on Thursday after the company posted a quarter-on-quarter decline in gross margins.</li>
<li>Other chip stocks felt the pressure post-Nvidia earnings. Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) fell nearly 1%, while Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) was down 0.6%. Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both fell 0.5% in premarket trading.</li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock surged over 10% on Wednesday and rose by another 11% in premarket trading on Thursday after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">crossed the $95,000 mark</a>. Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock was also up over 3%.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) shares rose over 21% in premarket trading after the company beat analyst expectations and revised its 2025 revenue outlook upwards.</li>
<li>Palo Alto Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) stock fell over 4% in premarket trading after the company's third-quarter results.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) stock was slightly down in premarket trading after the U.S. Department of Justice (DOJ) said the company needed to sell the Google Chrome browser to <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">end search monopoly</a>.</li>
<li>Investors are awaiting earnings results from Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>), and Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures surged in the early New York session, rising by 1.70% to hover around $69.92 per barrel.
The 10-year Treasury note yield edged lower to 4.394%.
Most of the major Asian markets ended in the red on Thursday, while European markets showed tentativeness in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">Target Says Shoppers Wait For &#8216;Deals&#8217; A Day After Rival Walmart Credits Market Gains To Wealthy Households</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Economics

Federal Reserve

Pre-Market Outlook

Movers

$BTC

AVGO

GOOG

GOOGL

HOOD

INTC

INTU

MSTR

NVDA

PANW

QCOM

SNOW

US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is 'Perfectly Normal,' But Late November Rally Is Still Possible

<ul>
<li>Digitally enabled comparable sales growth was 30.0%, reflecting two-year stacked comp growth of 47.0%</li>
<li>Membership fee income increased by 8.4% year-over-year to $115.0 million</li>
</ul>

BJ's Wholesale Club Q3 Comparable Club Sales Increased By 1.5% YoY, Comparable Club Sales, Excluding Gasoline Sales, Increased By 3.8% YoY, Led By Strong Traffic

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Warning: NXU is at high risk of performing badly

In a report released yesterday, Tate Sullivan from Maxim Group maintained a Hold rating on Nxu (NXU – Research Report). The company's shares opened...

Nxu (NXU) Gets a Hold from Maxim Group

Nxu (NXU) has shared an update. Nxu, Inc. shareholders have endorsed significant updates to the company's incentive plan, including an increased sh...

Nxu Shareholders Approve Incentives and Elect New Directors

An announcement from Nxu ( ($NXU) ) is now available. Nxu and Verde Bioresins have entered a merger agreement where Nxu will acquire Verde in an al...

Nxu and Verde Bioresins Merger Agreement Announcement

Nxu and Verde Bioresins entered into a merger agreement pursuant to which Nxu will acquire all of the issued and outstanding common shares of Verde...

Nxu Inc., Verde Bioresins enter merger agreement for all-stock transaction

Nxu shares jump on proposed merger with Verde Bioresins

Nxu has filed a registration statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed merger...

Nxu Inc. files registration statement on Form S-4 for proposed combination

Nxu ( ($NXU) ) has provided an announcement. Nxu, Inc. has announced a proposed merger with Verde Bioresins, Inc., which will see Nxu acquire Verde...

Nxu Proposes Merger with Verde Bioresins

Nxu ( ($NXU) ) has issued an update. Nxu, Inc. has announced a merger with Verde Bioresins, Inc., aiming to establish Verde as a wholly owned subsi...

Nxu Announces Merger with Verde Bioresins

AEMD

CARA

EEIQ

IONM

JILL

LGVN

PRFX

PTPI

ROMA

SIFYR

SQNS

VSME

XPON

Press Releases

NXU Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Nxu, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders

NXU INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Nxu, Inc. - NXU

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SASR, BMTX, NXU on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nxu, Inc. - NXU

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, BMTX, NXU, OB on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BMTX, NXU, PFIE on Behalf of Shareholders

Nxu, Inc. Files Registration Statement on Form S-4 for Proposed Business Combination with Verde Bioresins, Inc.

Kuehn Law Encourages NXU, B, KIO, and LBRDA Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NXU, LBRDA on Behalf of Shareholders

BMTX

LBRDA

LUMO

PFIE

RVNC

SASR

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Nxu

Nxu (NXU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga